# Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B: a real-world clinical study

## TL;DR

This study compares the effectiveness and safety of two hepatitis B treatments, finding that one offers better liver and kidney outcomes.

## Contribution

The study provides real-world evidence comparing TMF and TDF for chronic hepatitis B treatment.

## Key findings

- TMF showed higher ALT normalization and HBeAg seroconversion rates compared to TDF.
- TMF had a more favorable renal safety profile with lower serum creatinine levels.
- Virological response rates were similar between TMF and TDF.

## Abstract

To assess the real-world efficacy and safety of tenofovir amibufenamide (TMF) in patients with chronic hepatitis B (CHB) and to generate evidence to inform optimization of antiviral treatment selection in routine clinical practice.

This study enrolled 186 patients with CHB, of whom 93 received TMF and 93 received tenofovir disoproxil fumarate (TDF) for 48 weeks. The primary endpoint was the virological response rate. Secondary endpoints included the rate of serum alanine aminotransferase (ALT) normalization; changes in hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels; and changes in renal and bone metabolism markers, including serum creatinine, uric acid, calcium, and phosphate.

After 48 weeks of treatment, virological response rates did not differ significantly between the TMF and TDF groups (p > 0.05). In contrast, the ALT normalization rate was significantly higher in the TMF group than in the TDF group (76.34% vs. 60.22%, p < 0.05). Similarly, the HBeAg seroconversion rate was markedly higher with TMF therapy (22.78% vs. 9.21%, p < 0.05). With respect to safety, serum creatinine levels at week 48 were significantly lower in the TMF group compared with the TDF group (77.36 ± 16.87 μmol/L vs. 90.12 ± 17.23 μmol/L, p < 0.05). No significant between-group differences were observed in serum uric acid, calcium, or phosphate levels.

In real-world clinical practice, TMF is an effective treatment for CHB. Compared with TDF, TMF is associated with superior ALT normalization and higher HBeAg seroconversion rates, along with a more favorable renal safety profile.